BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

449 related articles for article (PubMed ID: 11531262)

  • 41. Modulation of DNA topoisomerase II activity and expression in melanoma cells with acquired drug resistance.
    Lage H; Helmbach H; Dietel M; Schadendorf D
    Br J Cancer; 2000 Jan; 82(2):488-91. PubMed ID: 10646909
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Ectopic expression of human topoisomerase IIalpha fragments and etoposide resistance in mammalian cells.
    Ernst AI; Soltermann A; Sigrist JA; Widmer L; Gasser SM; Stahel RA
    Int J Cancer; 2000 Oct; 88(1):99-107. PubMed ID: 10962446
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Altered expression and activity of topoisomerases during all-trans retinoic acid-induced differentiation of HL-60 cells.
    Aoyama M; Grabowski DR; Isaacs RJ; Krivacic KA; Rybicki LA; Bukowski RM; Ganapathi MK; Hickson ID; Ganapathi R
    Blood; 1998 Oct; 92(8):2863-70. PubMed ID: 9763571
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Transfection of human topoisomerase II alpha into etoposide-resistant cells: transient increase in sensitivity followed by down-regulation of the endogenous gene.
    Asano T; An T; Mayes J; Zwelling LA; Kleinerman ES
    Biochem J; 1996 Oct; 319 ( Pt 1)(Pt 1):307-13. PubMed ID: 8870683
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Expression of DNA topoisomerase IIalpha and topoisomerase IIbeta genes predicts survival and response to chemotherapy in patients with small cell lung cancer.
    Dingemans AM; Witlox MA; Stallaert RA; van der Valk P; Postmus PE; Giaccone G
    Clin Cancer Res; 1999 Aug; 5(8):2048-58. PubMed ID: 10473085
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Incidence of mutation and deletion in topoisomerase II mRNA of etoposide and m-AMSA resistant cell lines].
    Matsumoto Y; Morisaki K; Kunishio K; Nagao S; Takano H; Fojo T
    Gan To Kagaku Ryoho; 1998 Jul; 25(8):1145-9. PubMed ID: 9679576
    [TBL] [Abstract][Full Text] [Related]  

  • 47. In vivo etoposide-resistant C6 glioma cell line: significance of altered DNA topoisomerase II activity in multi-drug resistance.
    Taki T; Ohnishi T; Arita N; Hiraga S; Hayakawa T
    J Neurooncol; 1998 Jan; 36(1):41-53. PubMed ID: 9525824
    [TBL] [Abstract][Full Text] [Related]  

  • 48. E1A sensitizes HER2/neu-overexpressing Ewing's sarcoma cells to topoisomerase II-targeting anticancer drugs.
    Zhou Z; Jia SF; Hung MC; Kleinerman ES
    Cancer Res; 2001 Apr; 61(8):3394-8. PubMed ID: 11309298
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Enhanced topoisomerase I activity and increased topoisomerase II alpha content in cisplatin-resistant cancer cell lines.
    Minagawa Y; Kigawa J; Irie T; Kanamori Y; Itamochi H; Cheng X; Terakawa N
    Jpn J Cancer Res; 1997 Dec; 88(12):1218-23. PubMed ID: 9473741
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Induction of resistance to etoposide and adriamycin in a human glioma cell line treated with antisense oligodeoxynucleotide complementary to the messenger ribonucleic acid of deoxyribonucleic acid topoisomerase II alpha.
    Kuriyama M; Tsutsui K; Tsutsui K; Ono Y; Tamiya T; Matsumoto K; Furuta T; Ohmoto T
    Neurol Med Chir (Tokyo); 1997 Sep; 37(9):655-61; discussion 661-2. PubMed ID: 9330528
    [TBL] [Abstract][Full Text] [Related]  

  • 51. 2-[4-(7-chloro-2-quinoxalinyloxyphenoxy]-propionic acid (XK469), an inhibitor of topoisomerase (Topo) IIbeta, up-regulates Topo IIalpha and enhances Topo IIalpha-mediated cytotoxicity.
    Mensah-Osman EJ; Al-Katib AM; Wu HY; Osman NI; Mohammad RM
    Mol Cancer Ther; 2002 Dec; 1(14):1321-6. PubMed ID: 12516965
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Acquisition of multiple copies of a mutant topoisomerase IIalpha allele by chromosome 17 aneuploidy is associated with etoposide resistance in human melanoma cell lines.
    Campain JA; Slovak ML; Schoenlein PV; Popescu NC; Gottesman MM; Pastan I
    Somat Cell Mol Genet; 1995 Nov; 21(6):451-71. PubMed ID: 8600572
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Quantitation of DNA topoisomerase IIalpha and beta in human leukaemia cells by immunoblotting.
    Padget K; Pearson AD; Austin CA
    Leukemia; 2000 Nov; 14(11):1997-2005. PubMed ID: 11069037
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cell density-dependent VP-16 sensitivity of leukaemic cells is accompanied by the translocation of topoisomerase IIalpha from the nucleus to the cytoplasm.
    Valkov NI; Gump JL; Engel R; Sullivan DM
    Br J Haematol; 2000 Feb; 108(2):331-45. PubMed ID: 10691864
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Human topoisomerase IIalpha and IIbeta interact with the C-terminal region of p53.
    Cowell IG; Okorokov AL; Cutts SA; Padget K; Bell M; Milner J; Austin CA
    Exp Cell Res; 2000 Feb; 255(1):86-94. PubMed ID: 10666337
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Gambogic acid inhibits the catalytic activity of human topoisomerase IIalpha by binding to its ATPase domain.
    Qin Y; Meng L; Hu C; Duan W; Zuo Z; Lin L; Zhang X; Ding J
    Mol Cancer Ther; 2007 Sep; 6(9):2429-40. PubMed ID: 17876042
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A truncated cytoplasmic topoisomerase IIalpha in a drug-resistant lung cancer cell line is encoded by a TOP2A allele with a partial deletion of exon 34.
    Mirski SE; Sparks KE; Yu Q; Lang AJ; Jain N; Campling BG; Cole SP
    Int J Cancer; 2000 Feb; 85(4):534-9. PubMed ID: 10699927
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Expression of DNA topoisomerase I, IIalpha, and IIbeta in human brain tumors.
    Morisaki K; Kuroda S; Matsumoto Y; Kunishio K; Nagao S
    Brain Tumor Pathol; 2000; 17(1):7-13. PubMed ID: 10982004
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Loss of amino acids 1490Lys-Ser-Lys1492 in the COOH-terminal region of topoisomerase IIalpha in human small cell lung cancer cells selected for resistance to etoposide results in an extranuclear enzyme localization.
    Wessel I; Jensen PB; Falck J; Mirski SE; Cole SP; Sehested M
    Cancer Res; 1997 Oct; 57(20):4451-4. PubMed ID: 9377550
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
    Wessel I; Jensen LH; Jensen PB; Falck J; Rose A; Roerth M; Nitiss JL; Sehested M
    Cancer Res; 1999 Jul; 59(14):3442-50. PubMed ID: 10416608
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.